Posts

Autism Spectrum Disorder (ASD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Autism Spectrum Disorder (ASD) Market Outlook Thelansis’s “Autism Spectrum Disorder (ASD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autism Spectrum Disorder (ASD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Autism Spectrum Disorder (ASD) Overview Autism spectrum disorder (ASD) is a complex, highly heterogeneous neurodevelopmental condition clinically defined by two core diagnostic domains: persistent deficits in social communication and reciprocal interaction across multiple contexts, alongside the presence of restricted, repetitive patterns of behavior, interests, or activities. While the etiology is multifactor...
Post a Comment
Read more

Essential Tremor (ET) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Essential Tremor (ET) Market Outlook Thelansis’s “Essential Tremor (ET) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Essential Tremor (ET) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Essential Tremor (ET) Overview Essential tremor (ET) is one of the most common adult movement disorders, characterized as a chronic, progressive neurological condition manifesting primarily as a symmetric kinetic and postural tremor. It predominantly affects the upper extremities, though the head, voice, and lower limbs can be involved. Unlike Parkinson’s disease, the tremor is typically absent at rest and worsens during voluntary, goal...
Post a Comment
Read more

Fabry Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Fabry Disease Market Outlook Thelansis’s “Fabry Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fabry Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Fabry Disease Overview Fabry disease, a rare genetic metabolic storage disorder, results in the progressive failure of organs and premature death. It arises from a mutation in the galactosidase alpha gene, causing a deficiency or absence of α-galactosidase A (GALA), a lysosomal enzyme. Consequently, this deficiency impairs the breakdown of globotriaosylceramide (Gb3) and related glycosphingolipids, gradually accumulating Gb3 and glycosphingolipids within lysos...
Post a Comment
Read more

Friedreich Ataxia (FA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Friedreich Ataxia (FA) Market Outlook Thelansis’s “Friedreich Ataxia (FA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Friedreich Ataxia (FA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Friedreich Ataxia (FA) Overview Friedreich’s ataxia is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansion in the FXN gene, reducing frataxin protein and impairing mitochondrial iron handling, leading to oxidative neuronal injury. It presents with progressive gait and limb ataxia, dysarthria, areflexia, sensory loss, and cardiomyopathy, with scoliosis and diabetes as common systemic features...
Post a Comment
Read more

Tourette Syndrome (TS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Tourette Syndrome (TS) Market Outlook Thelansis’s “Tourette Syndrome (TS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Tourette Syndrome (TS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Tourette Syndrome (TS) Overview Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder characterized by chronic, fluctuating motor and vocal tics, driven by dopaminergic pathway dysregulation within cortico-striato-thalamo-cortical brain circuits. Diagnosis is established clinically under DSM-5 criteria, requiring multiple motor tics and at least one vocal tic with onset before age 18, persisting for greater than one...
Post a Comment
Read more

IgA Nephropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

IgA Nephropathy Market Outlook Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). IgA Nephropathy Overview IgA Nephropathy is the most common primary glomerulonephritis, caused by mesangial deposition of galactose-deficient IgA1 immune complexes, triggering complement activation and progressive glomerular injury. It presents with recurrent gross hematuria or persistent microscopic hematuria and proteinuria. Renal biopsy with immunofluorescence confirms diagnosis; proteinuria at or above 0.5g/day, hypertension, and reduced eGFR define ...
Post a Comment
Read more

Fibrostenotic Crohn’s Disease (FSCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Fibrostenotic Crohn’s Disease (FSCD) Market Outlook Thelansis’s “Fibrostenotic Crohn’s Disease (FSCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fibrostenotic Crohn’s Disease (FSCD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Fibrostenotic Crohn’s Disease (FSCD) Overview Fibrostenotic Crohn’s disease (FSCD) is a complications-driven phenotypic subtype of Crohn’s disease, not an independent condition, where chronic transmural inflammation causes irreversible extracellular matrix deposition and fixed mechanical strictures. Patients present with postprandial cramping and vomiting, though narrowings can develop silent...
Post a Comment
Read more